» Articles » PMID: 37004753

Receptor Expression and Signaling Properties in the Brain, and Structural Ligand Motifs That Contribute to Delta Opioid Receptor Agonist-induced Seizures

Overview
Specialties Neurology
Pharmacology
Date 2023 Apr 2
PMID 37004753
Authors
Affiliations
Soon will be listed here.
Abstract

The δ opioid receptor (δOR) is a therapeutic target for the treatment of various neurological disorders, such as migraines, chronic pain, alcohol use, and mood disorders. Relative to μ opioid receptor agonists, δOR agonists show lower abuse liability and may be potentially safer analgesic alternatives. However, currently no δOR agonists are approved for clinical use. A small number of δOR agonists reached Phase II trials, but ultimately failed to progress due to lack of efficacy. One side effect of δOR agonism that remains poorly understood is the ability of δOR agonists to produce seizures. The lack of a clear mechanism of action is partly driven by the fact that δOR agonists range in their propensity to induce seizure behavior, with multiple δOR agonists reportedly not causing seizures. There is a significant gap in our current understanding of why certain δOR agonists are more likely to induce seizures, and what signal-transduction pathway and/or brain area is engaged to produce these seizures. In this review we provide a comprehensive overview of the current state of knowledge of δOR agonist-mediated seizures. The review was structured to highlight which agonists produce seizures, which brain regions have been implicated and which signaling mediators have been examined in this behavior. Our hope is that this review will spur future studies that are carefully designed and aimed to solve the question why certain δOR agonists are seizurogenic. Obtaining such insight may expedite the development of novel δOR clinical candidates without the risk of inducing seizures. This article is part of the Special Issue on "Opioid-induced changes in addiction and pain circuits".

Citing Articles

Opioid receptor signaling throughout ontogeny: Shaping neural and behavioral trajectories.

Spodnick M, McElderry S, Diaz M Neurosci Biobehav Rev. 2025; 170:106033.

PMID: 39894419 PMC: 11851333. DOI: 10.1016/j.neubiorev.2025.106033.


Cryo-EM structure of small-molecule agonist bound delta opioid receptor-G complex enables discovery of biased compound.

Cheng L, Miao Z, Liu S, Li Z, Fu H, Xu C Nat Commun. 2024; 15(1):8284.

PMID: 39333070 PMC: 11437176. DOI: 10.1038/s41467-024-52601-1.


Design, Synthesis, and Characterization of New δ Opioid Receptor-Selective Fluorescent Probes and Applications in Single-Molecule Microscopy of Wild-Type Receptors.

Drakopoulos A, Koszegi Z, Seier K, Hubner H, Maurel D, Sounier R J Med Chem. 2024; 67(15):12618-12631.

PMID: 39044606 PMC: 11386433. DOI: 10.1021/acs.jmedchem.4c00627.


Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel Opioid Receptor-Selective Agonist Chemotype.

Meqbil Y, Aguilar J, Blaine A, Chen L, Cassell R, Pradhan A J Pharmacol Exp Ther. 2024; 389(3):301-309.

PMID: 38621994 PMC: 11125782. DOI: 10.1124/jpet.123.001735.

References
1.
Eid T, Thomas M, Spencer D, Runden-Pran E, Lai J, Malthankar G . Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet. 2004; 363(9402):28-37. DOI: 10.1016/s0140-6736(03)15166-5. View

2.
Spahn V, Stein C . Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs. 2016; 26(2):155-160. DOI: 10.1080/13543784.2017.1275562. View

3.
Kendall R, Lee M, Pleasant D, Robinson K, Kuppuswamy D, McDermott P . Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J Biol Chem. 2014; 289(38):26155-26166. PMC: 4176252. DOI: 10.1074/jbc.M114.595728. View

4.
Jutkiewicz E, Kaminsky S, Rice K, Traynor J, Woods J . Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther. 2005; 315(1):414-22. PMC: 1307500. DOI: 10.1124/jpet.105.088831. View

5.
Yamada D, Yanagisawa S, Yoshizawa K, Yanagita S, Oka J, Nagase H . Selective agonists of the δ-opioid receptor, KNT-127 and SNC80, act differentially on extinction learning of contextual fear memory in mice. Neuropharmacology. 2019; 160:107792. DOI: 10.1016/j.neuropharm.2019.107792. View